questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Antigènes B7
Antigène CD274
Antigène CD274 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Neovascularization, Pathologic
Diagnostic
5
Antigène CD274
Immunohistochimie
Cancer du poumon
Cancer du sein
Lymphocytes T
Système immunitaire
Symptômes
5
Immunosuppression
Infections
Maladies auto-immunes
Cellules T
Réponse immunitaire
Infections
Tests cliniques
Symptômes
Prévention
5
Prévention
Expression génique
Mode de vie sain
Système immunitaire
Détection précoce
Gestion du cancer
Habitudes alimentaires
Expression génique
Traitements
5
Inhibiteurs de PD-1
Pembrolizumab
Thérapies immunologiques
Réponse immunitaire
Thérapie génique
Expression génique
Effets secondaires
Réactions auto-immunes
Efficacité des traitements
Profil immunitaire
Complications
5
Immunosuppression
Progression tumorale
Maladies auto-immunes
Infections chroniques
Résistance aux traitements
Thérapies immunologiques
Survie des patients
Pronostic
Complications
Traitement approprié
Facteurs de risque
5
Facteurs de risque
Antécédents de cancer
Tabagisme
Cancer du poumon
Obésité
Expression génique
Infections virales
Cellules immunitaires
Stress chronique
Réponse immunitaire
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigène CD274 : Questions médicales les plus fréquentes",
"headline": "Antigène CD274 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigène CD274 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-16",
"dateModified": "2025-05-11",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigène CD274"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Antigènes B7",
"url": "https://questionsmedicales.fr/mesh/D060887",
"about": {
"@type": "MedicalCondition",
"name": "Antigènes B7",
"code": {
"@type": "MedicalCode",
"code": "D060887",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.168"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigène CD274",
"alternateName": "B7-H1 Antigen",
"code": {
"@type": "MedicalCode",
"code": "D060890",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Soldano Ferrone",
"url": "https://questionsmedicales.fr/author/Soldano%20Ferrone",
"affiliation": {
"@type": "Organization",
"name": "Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA."
}
},
{
"@type": "Person",
"name": "Haidong Dong",
"url": "https://questionsmedicales.fr/author/Haidong%20Dong",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Mayo Clinic, Rochester, MN, USA."
}
},
{
"@type": "Person",
"name": "Hongwei Du",
"url": "https://questionsmedicales.fr/author/Hongwei%20Du",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA."
}
},
{
"@type": "Person",
"name": "Barbara Savoldo",
"url": "https://questionsmedicales.fr/author/Barbara%20Savoldo",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA."
}
},
{
"@type": "Person",
"name": "Gianpietro Dotti",
"url": "https://questionsmedicales.fr/author/Gianpietro%20Dotti",
"affiliation": {
"@type": "Organization",
"name": "Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA. Electronic address: gdotti@med.unc.edu."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Downregulation of PIK3IP1 in retinal microglia promotes retinal pathological neovascularization via PI3K-AKT pathway activation.",
"datePublished": "2023-08-07",
"url": "https://questionsmedicales.fr/article/37550343",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-39473-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Novel theranostic approaches to neovascularized atherosclerotic plaques.",
"datePublished": "2023-05-02",
"url": "https://questionsmedicales.fr/article/37149970",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.atherosclerosis.2023.04.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hyperacute iris neovascularization following cataract surgery.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35801772",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/MD.0000000000029356"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hyperreflective material in patients with non-neovascular pachychoroid disease.",
"datePublished": "2023-06-06",
"url": "https://questionsmedicales.fr/article/37280611",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12886-023-03011-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Two-year outcomes of treat-and-extend regimen with intravitreal brolucizumab for treatment-naïve neovascular age-related macular degeneration with type 1 macular neovascularization.",
"datePublished": "2023-02-24",
"url": "https://questionsmedicales.fr/article/36828853",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-023-30146-5"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Antigènes B7",
"item": "https://questionsmedicales.fr/mesh/D060887"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antigène CD274",
"item": "https://questionsmedicales.fr/mesh/D060890"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigène CD274 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigène CD274",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-19",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigène CD274",
"description": "Comment diagnostiquer une expression anormale de CD274 ?\nQuels tests sanguins sont utilisés pour CD274 ?\nCD274 est-il associé à des biomarqueurs spécifiques ?\nQuels types de cancers montrent une surexpression de CD274 ?\nComment évaluer l'impact de CD274 sur le système immunitaire ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Neovascularization,+Pathologic#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigène CD274",
"description": "Quels symptômes sont liés à une surexpression de CD274 ?\nCD274 influence-t-il les symptômes des maladies auto-immunes ?\nY a-t-il des symptômes spécifiques au cancer liés à CD274 ?\nComment CD274 affecte-t-il la réponse aux infections ?\nLes symptômes de CD274 sont-ils visibles cliniquement ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Neovascularization,+Pathologic#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigène CD274",
"description": "Peut-on prévenir l'expression de CD274 ?\nComment un mode de vie sain influence-t-il CD274 ?\nY a-t-il des vaccins ciblant CD274 ?\nLa détection précoce des cancers aide-t-elle à gérer CD274 ?\nLes habitudes alimentaires influencent-elles CD274 ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Neovascularization,+Pathologic#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigène CD274",
"description": "Quels traitements ciblent CD274 ?\nComment les thérapies immunologiques agissent-elles sur CD274 ?\nCD274 peut-il être une cible pour la thérapie génique ?\nQuels effets secondaires sont associés aux traitements ciblant CD274 ?\nLes traitements de CD274 sont-ils efficaces pour tous les cancers ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Neovascularization,+Pathologic#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigène CD274",
"description": "Quelles complications sont liées à une surexpression de CD274 ?\nCD274 peut-il aggraver des maladies existantes ?\nY a-t-il des risques de résistance aux traitements avec CD274 ?\nComment CD274 influence-t-il la survie des patients ?\nLes complications de CD274 sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Neovascularization,+Pathologic#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigène CD274",
"description": "Quels facteurs augmentent le risque d'expression de CD274 ?\nLe tabagisme influence-t-il CD274 ?\nY a-t-il un lien entre l'obésité et CD274 ?\nLes infections virales affectent-elles CD274 ?\nLe stress chronique influence-t-il CD274 ?",
"url": "https://questionsmedicales.fr/mesh/D060890?mesh_terms=Neovascularization,+Pathologic#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une expression anormale de CD274 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests immunohistochimiques peuvent être utilisés pour détecter CD274 dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utilisés pour CD274 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages de cytokines et des tests de surface cellulaire peuvent évaluer CD274."
}
},
{
"@type": "Question",
"name": "CD274 est-il associé à des biomarqueurs spécifiques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 est souvent associé à des biomarqueurs de cancer comme PD-1."
}
},
{
"@type": "Question",
"name": "Quels types de cancers montrent une surexpression de CD274 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les cancers du poumon, du sein et de la vessie montrent souvent une surexpression de CD274."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'impact de CD274 sur le système immunitaire ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études fonctionnelles sur les lymphocytes T peuvent évaluer l'impact de CD274."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une surexpression de CD274 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surexpression de CD274 peut entraîner une immunosuppression et des infections fréquentes."
}
},
{
"@type": "Question",
"name": "CD274 influence-t-il les symptômes des maladies auto-immunes ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 peut exacerber les symptômes des maladies auto-immunes en inhibant les cellules T."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques au cancer liés à CD274 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure la fatigue, la perte de poids et des douleurs localisées."
}
},
{
"@type": "Question",
"name": "Comment CD274 affecte-t-il la réponse aux infections ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une expression élevée de CD274 peut réduire l'efficacité de la réponse immunitaire aux infections."
}
},
{
"@type": "Question",
"name": "Les symptômes de CD274 sont-ils visibles cliniquement ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, CD274 n'a pas de symptômes visibles, mais son impact est observé par des tests."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'expression de CD274 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode spécifique pour prévenir l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Comment un mode de vie sain influence-t-il CD274 ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut renforcer le système immunitaire, potentiellement régulant CD274."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccins ciblant CD274 ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de vaccins spécifiquement ciblant CD274."
}
},
{
"@type": "Question",
"name": "La détection précoce des cancers aide-t-elle à gérer CD274 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la détection précoce peut permettre une intervention rapide sur l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles CD274 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent que l'alimentation peut moduler l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent CD274 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les inhibiteurs de PD-1 et PD-L1, comme le pembrolizumab, ciblent CD274."
}
},
{
"@type": "Question",
"name": "Comment les thérapies immunologiques agissent-elles sur CD274 ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles bloquent l'interaction entre CD274 et PD-1, stimulant ainsi la réponse immunitaire."
}
},
{
"@type": "Question",
"name": "CD274 peut-il être une cible pour la thérapie génique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches explorent la thérapie génique pour moduler l'expression de CD274."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires sont associés aux traitements ciblant CD274 ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des réactions auto-immunes et des inflammations."
}
},
{
"@type": "Question",
"name": "Les traitements de CD274 sont-ils efficaces pour tous les cancers ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'efficacité varie selon le type de cancer et le profil immunitaire du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications sont liées à une surexpression de CD274 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent une immunosuppression accrue et une progression tumorale."
}
},
{
"@type": "Question",
"name": "CD274 peut-il aggraver des maladies existantes ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, CD274 peut aggraver des maladies auto-immunes et des infections chroniques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de résistance aux traitements avec CD274 ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la surexpression de CD274 peut entraîner une résistance aux thérapies immunologiques."
}
},
{
"@type": "Question",
"name": "Comment CD274 influence-t-il la survie des patients ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une expression élevée de CD274 est souvent associée à un pronostic défavorable dans le cancer."
}
},
{
"@type": "Question",
"name": "Les complications de CD274 sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque d'expression de CD274 ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents de cancer, des infections chroniques et l'âge."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il CD274 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut augmenter l'expression de CD274, surtout dans le cancer du poumon."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien entre l'obésité et CD274 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études montrent que l'obésité peut être associée à une expression accrue de CD274."
}
},
{
"@type": "Question",
"name": "Les infections virales affectent-elles CD274 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections virales peuvent induire l'expression de CD274 dans les cellules immunitaires."
}
},
{
"@type": "Question",
"name": "Le stress chronique influence-t-il CD274 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut moduler l'expression de CD274, affectant la réponse immunitaire."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 11/05/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Department of Urology, Mayo Clinic, Rochester, MN, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Pediatrics, University of North Carolina, Chapel Hill, NC, USA.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC, USA. Electronic address: gdotti@med.unc.edu.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Department of Neurosurgery West China Hospital West China Medical School Sichuan University Chengdu China.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
State Key Laboratory of Biotherapy West China Hospital West China Medical School Sichuan University Chengdu China.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
Department of Neurosurgery West China Hospital West China Medical School Sichuan University Chengdu China.
Publications dans "Antigène CD274" :
3 publications dans cette catégorie
Affiliations :
State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, SZ, China.
Jiangsu Institute of Clinical Immunology, The First Affiliated Hospital of Soochow University, Suzhou, SZ, China.
SuZhou Bright Scistar Antibody Biotech co., Ltd, 303-305, Bldg 15, NO.8, Jinfeng Road, Suzhou, SZ, China.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Medical University of Graz, Graz, Austria.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Medical University of Graz, Graz, Austria.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Hematology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, 100 Haining Road, Shanghai, 200080, China.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Urology, Mayo Clinic, Rochester, MN, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Immunology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Department of Internal Medicine, Ohio State University College of Medicine and Wexner Medical Center, Columbus, OH 43210, USA. Electronic address: songguozheng2013@yahoo.com.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
Royal Veterinary Collegegrid.20931.39, London, United Kingdom.
OIE/FAO International Reference Laboratory for Avian Influenza, Swine Influenza and Newcastle Disease, Animal and Plant Health Agency (APHA), Weybridge, Addlestone, Surrey, United Kingdom.
Publications dans "Antigène CD274" :
2 publications dans cette catégorie
Affiliations :
National Animal Disease Center, USDA-ARS, Ames, Iowa, USA.
Publications dans "Antigène CD274" :
Retinal pathological neovascularization involves endothelial cells, pericytes, photoreceptor cells, ganglion cells, and glial cells, whose roles remain unclear. Using the Scissor algorithm, we found t...
As the global burden of atherosclerotic cardiovascular disease continues to rise, there is an increased demand for improved imaging techniques for earlier detection of atherosclerotic plaques and new ...
We describe a case of acute neovascularization of the iris after uneventful cataract surgery....
A 78-year-old man visited our clinic for cataract surgery and glaucoma management....
The patient underwent bilateral laser iridotomy 4 years ago. On ocular examination, the best-corrected visual acuity was no light perception in the right eye and 20/100 in the left eye. We observed ps...
The patient underwent cataract surgery in the left eye without complications....
The day after surgery we observed 360° of neovascularization in the iris and aggravated hemi-CRVO with macular edema. Therefore, we administered intravitreal bevacizumab in the left eye, after which t...
Cataract surgery can rapidly aggravate hemi-CRVO and cause iris neovascularization, which is responsive to bevacizumab....
This study aimed to report eleven cases of non-neovascular pachychoroid disease with hyperreflective material (HRM) that occurred in Japanese patients....
A retrospective review of data from eleven patients who had non-neovascular retinal pigment epithelium (RPE) protrusion with HRM in the neurosensory retina between March 2017 and June 2022 was conduct...
All cases had RPE protrusion and HRM with dilated choroidal veins, which were characteristic of pachychoroid disease. However, none of the cases had macular neovascularization (MNV). In 9 eyes (81.8%)...
There are some cases of non-neovascular pachychoroid disorder with HRM, which might be a new entity of pachychoroid spectrum disease or an early stage of PPE or FCE. These cases should not be misdiagn...
We previously reported one-year results of a treat-and-extend (TAE) regimen with intravitreal brolucizumab for 68 eyes with treatment-naïve neovascular age-related macular degeneration (nAMD) associat...
Diabetic retinopathy (DR) is a common complication of diabetes, and recent findings have shown that long noncoding RNAs (lncRNAs) may be involved in its pathogenesis. Through bioinformatics analysis, ...
We used RT‒PCR to assess the expression levels of lncRNA ATP2B2-IT2 and vascular endothelial growth factor (VEGF) in HRMECs under normal glucose (5.5 mmol/L) and high glucose (30 mmol/L) conditions. H...
RT‒PCR revealed that the expression levels of the lncRNA ATP2B2-IT2 and VEGF were greater in the HG group than in the NG group (P < 0.05). After silencing of the lncRNA ATP2B2-IT2, the expression of V...
LncRNA ATP2B2-IT2 may promote the proliferation, migration and neovascularization of HRMECs under high-glucose conditions....
To report the cumulative incidence and risk factors of second eye involvement after diagnosis of myopic macular neovascularization (MNV) in the first eye....
Retrospective analysis of longitudinal data from a tertiary hospital in the Netherlands....
Patients with high myopia (spherical equivalent [SE] ≤ - 6 diopters [D]), of European ethnicity, who were diagnosed with active MNV lesion in 1 eye between 2005 and 2018. Fellow eyes were free of MNV ...
Incidence rate and 2-, 5-, and 10-year cumulative incidences were calculated; hazard ratios (HRs) of second eye involvement were analyzed for potential risk factors using Cox proportional hazard model...
Incidence of second eye involvement after onset of myopic MNV in the first eye....
We included 88 patients over a period of 13 years with a mean age of 58 ± 15 years, mean axial length of 30 ± 1.7 mm and SE -14 ± 4 D at baseline. Twenty-four fellow eyes (27%) developed a myopic MNV ...
Our study of high myopes of European descent shows very similar incidence rates for second eye myopic MNV compared with Asian studies. Our findings substantiate the importance for clinicians to monito...
The authors have no proprietary or commercial interest in any materials discussed in this article....
To examine the role of CCL14 in the neovascularization process and vulnerability progression within carotid plaques by investigating the mechanism of CCL14 regulation of VEGF-A....
We first performed histological analysis and immunohistochemical staining of human carotid plaque tissue to detect the expression of CCL14, JAK2, STAT3 and VEGF-A. We next examined the protein express...
Histological and Western blotting analysis of human carotid plaque samples showed that the expression of CCL14 and VEGF-A was higher in the vulnerable plaques than in stable plaques. In the in vitro c...
In the human carotid plaques, CCL14 promotes angiogenesis by upregulation of VEGF-A via JAK2/STAT3 pathway and thus drives the progression of carotid plaques vulnerability....
To report the incidence and risk factors associated with ocular neovascularization (NV) in patients with central retinal artery occlusion (CRAO)....
This retrospective study included patients diagnosed with acute CRAO in a single tertiary center. Medical charts were reviewed for ocular NV occurrences. We analyzed systemic and ocular conditions on ...
Eighty-seven eyes were eligible for this study. Among these, 13 eyes had ocular NV after CRAO, with an incidence of 15%. The prevalences of hypertension, diabetes mellitus, history of stroke, chronic ...
CKD and glaucoma history were significant risk factors for developing ocular NV after CRAO, particularly among patients that underwent dialysis....
Angiogenesis is the biological process in which existing blood vessels generate new ones and it is essential for body growth and development, wound healing, and granulation tissue formation. Vascular ...